Arecor Therapeutics plc announced that it has signed an agreement with a top 10 pharmaceutical company to develop an enhanced antibody formulation for one of its investigational drugs. Under the terms of this agreement, Arecor will use its proprietary formulation technology platform, Arestattm, to develop a novel, stable formulation of a liquid, high concentration antibody. The collaborator will fund the development work, generating new revenue for Arecor.

This agreement adds to Arecor's growing portfolio of partnerships.